Group Profile
Cordyceps Sunshine Biotech Holdings Co., Ltd. (“C.S. Group”) is a Cayman Islands–incorporated biotechnology company and a recognized expert in the field of rare and valuable medicinal fungi. Built on innovative agricultural biotechnology, we focus on the cultivation and scalable production of scarce medicinal fungi with global potential.
We are the exclusive cultivator of two of China’s most important medicinal fungi—Taiwanofungus camphoratus (Antrodia cinnamomea) and Cordyceps—and hold multiple patented technologies that enable efficient, scalable production. Our group also owns the well-known wellness brand KASAER, guided by a clear set of core values: environmental responsibility, purity from natural origins, and strict quality control from the source. Through a food-as-medicine philosophy, KASAER is committed to supporting the body’s natural self-healing ability and promoting premium wellness for consumers of all ages.
Within the Taiwanofungus camphoratus (Antrodia cinnamomea) industry, we have broken through key technical barriers and successfully cultivated fruiting bodies that match wild-grade standards in both composition and appearance. This achievement helps fill a long-standing supply gap since Taiwan prohibited the harvesting of wild Taiwanofungus camphoratus (Antrodia cinnamomea) in 2015. We have filed patents across Taiwan, Mainland China, Japan, and the United States covering Taiwanofungus camphoratus (Antrodia cinnamomea) cultivation methods and proprietary porous substrates, and have successfully commercialized these innovations for large-scale cultivation. Our approach addresses a major industry challenge by overcoming the limitations of liquid mycelium cultivation, which often results in lower efficacy products.
We operate Taiwanofungus camphoratus (Antrodia cinnamomea) cultivation and production facilities in both Taiwan and Mainland China, providing the market with safe, reliable, and effective Taiwanofungus camphoratus (Antrodia cinnamomea) raw materials. We have also established Taiwan’s largest Taiwanofungus camphoratus (Antrodia cinnamomea) retail chain, strengthening our leadership and market reach. In 2025, we successfully extracted and purified Antcin A, a key bioactive compound from Taiwanofungus camphoratus (Antrodia cinnamomea), and developed a novel combination veterinary drug targeting the global veterinary steroid medication market, valued at over US$10 billion annually.
We are advancing two key growth engines— Premium Fungal Raw Materials and Pet Pharmaceutical Development.
Premium Rare Medicinal Fungus – Taiwanofungus camphoratus
Taiwan is home to one of the world’s most rare and highly regarded premium medicinal fungi—Taiwanofungus camphoratus (Antrodia cinnamomea). Long valued in local tradition, it was first documented in folk records as a wellness ingredient used by Taiwan’s indigenous communities, and later became part of specialized herbal formulations passed down by traditional practitioners. Over the past two decades, extensive scientific research has further validated its wellness potential, with more than a thousand academic studies published worldwide supporting its health-related benefits.
With years of extensive experience in cultivating Taiwanofungus camphoratus (Antrodia cinnamomea), our company achieved a major breakthrough in 2020. By optimizing fungal strains and leveraging our patented ceramic cultivation substrate, we successfully produced TF-15, a fruiting body rich in Antcin A. Supported by a fully traceable production system and professional large-scale cultivation facilities, we manage the entire value chain in-house—from strain optimization and cultivation technology to scalable production, extraction and purification, and most recently, veterinary drug development. This end-to-end capability enables us to deliver premium Taiwanofungus camphoratus (Antrodia cinnamomea) ingredients that are scientifically measurable, consistently controlled in quality, and safe and reliable for the market—building a strong foundation for expansion across the Greater China wellness sector and broader pharmacological research applications.
Novel Compound Veterinary Drug Development
C.S. Group has recognized that the benefits of Taiwanofungus camphoratus extend beyond human wellness, demonstrating immense potential in the field of pet healthcare. To align with PIC/S GMP international pharmaceutical manufacturing standards and explore the pharmacological applications of its bioactive compounds, the Group invested nearly NT$100 million in 2025 to establish a dedicated Antcin A Drug Research Laboratory.
Our strategic approach to pet drug development focuses on the high-demand markets associated with the top ten most common pet diseases. Specifically, we are targeting the global pet steroid market, which is valued at over US$10 billion annually. Our mission is to provide a fundamental solution that addresses the physical strain and severe side effects caused by long-term steroid use in pets, offering a safer and more effective therapeutic alternative.
Laboratory results have confirmed that Antcin A exhibits anti-inflammatory properties comparable to those of steroids. Subsequently, our proprietary TF-15 raw material (containing high concentrations of Antcin A) was combined with the steroid Dexamethasone (DXMS) for lung cancer cell line experiments. Preliminary results demonstrate a significant synergistic effect. The experimental validations are summarized as follows:
Species Authentication: DNA sequencing of the TF-15 raw material has definitively identified it as the Taiwanofungus camphoratus species.
Grade Equivalence: Analytical testing confirms that TF-15 is equivalent in grade to high-quality Taiwanofungus camphoratus fruiting bodies cultivated via traditional wood-log methods.
Advanced Extraction Process: Utilizing a dual-extraction method—aqueous extraction to remove impurities followed by ethanol extraction—we have successfully obtained high-purity Antcin A from TF-15.
Synergistic Potential: The combination of Antcin A and Dexamethasone has been proven to possess the potential for a synergistic effect in inhibiting and reversing cancer cell progression.
Choosing to test our novel drug in the animal health sector provides a competitive edge:
Optimized Formulations: Allows for the development of pet-specific delivery systems (e.g., oral liquids/chews) based on proven safety data.
Clinical Acceleration: Provides a critical data bridge that shortens the trajectory for human clinical trials.
Market Synergy: Scientific insights can be cross-leveraged to boost the credibility of our pet and human supplement lines.
This is a highly resilient strategy that balances proactive innovation with stable market foundations.
According to data from the market research firm Valuates Reports, the global market for steroids in pet healthcare reached US$38.3 billion in 2021 and continues to show steady annual growth. Locally, the Taiwan market for veterinary steroid injectables exceeded NT$1.5 billion in 2022, with a projected Compound Annual Growth Rate (CAGR) of 5.2% over the next five years. Industry evidence confirms that Taiwanofungus camphoratus can mitigate the side effects associated with traditional steroid use. Integrating this into a combined therapy with veterinary steroids is expected to unlock significant market value.
In 2025, C.S. Group officially proposed a novel combination therapy—Antcin A in conjunction with steroids—and initiated the application for a New Compound Veterinary Drug Certificate in Taiwan. The first phase, involving background data review and pharmacokinetic (PK) testing, was successfully completed in mid-2025. We are on schedule to launch the second phase, toxicological safety testing, in the first quarter of 2026.
